{"groups":[{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\\> \\> Atezolizumab: Given IV\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Fluorouracil: Given IV\\>\n\n\\> Leucovorin Calcium: Given IV\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Oxaliplatin: Given IV\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"FG000","title":"Arm I (Combination Chemotherapy, Atezolizumab)"},{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Fluorouracil: Given IV\\>\n\n\\> Leucovorin Calcium: Given IV\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Oxaliplatin: Given IV\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"FG001","title":"Arm II (Combination Chemotherapy)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Disease progression prior to beginning treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"25"}],"type":"Patient withdrawal prior to beginning treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Unknown - prior to beginning treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"13"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"32"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Alternative therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"76"},{"groupId":"FG001","numSubjects":"51"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"14"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"355"},{"groupId":"FG001","numSubjects":"357"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"163"},{"groupId":"FG001","numSubjects":"214"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"192"},{"groupId":"FG001","numSubjects":"143"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}